Inspiration Healthcare Group (IHC)

Sector:

Industrial Chemicals

Index:

FTSE AIM All-Share

 17.25p
   
  • Change Today:
      0.000p
  • 52 Week High: 53.50p
  • 52 Week Low: 15.85p
  • Currency: UK Pounds
  • Shares Issued: 89.66m
  • Volume: 6,500
  • Market Cap: £15.47m
  • RiskGrade: 227

CureVac rejects reports of White House takeover offer for COVID-19 vaccine

By Alexander Bueso

Date: Wednesday 18 Mar 2020

LONDON (ShareCast) - (Sharecast News) - CureVac has rejected a report at the weekend that the White House had offered to buy out the German-US biotechnology outfit that is developing a possible vaccine for the COVID-19 coronavirus.
In a conference call with journalists, the company did however confirm that it was working with the US Defense Advanced Research Projects Agency and other agencies in America, such as the National Institutes of Health.

It was also in talks with the German government.

But an executive from the company indicated that the report from Welt am Sonntag was not correct, with another saying the firm "did not know" where such information had originated from and therefore could not comment on the reports.

The newspaper, which cited an anonymous source within the German government, said that the White House was pushing for exclusive access to the supply of the vaccine.

CureVac also said it had received no such approach, although it did not know if other conversations might have taken place in the background that it was unaware of.

Two senior American officials had told the New York Times on Sunday that some of the German news accounts first reporting the story were overblown, particularly with regards to any effort by the United States "to secure exclusive access to a vaccine".

And one German official told the NYT it was not clear if the US was just seeking access to the coronavirus research and for production to be conducted on American soil.

A Coronavirus vaccine may be possible by autumn

On Tuesday evening, European Commission chief, Ursula Von der Leyen, said that the European Commission would do everything in its power to try and develop a vaccine by autumn 2020.

Typically, experts say that a normal timeline for developing a vaccine is more on the order of a year or a year and a half.

Von der Leyen, however, believed that timeline could potentially be reduced in half or two-thirds by accelerating the bureaucratic processes involved, AFP reported.

She referred specifically to a company "that other countries want to buy out, meaning that it is the leader", reportedly adding that the company believed that it might be possible to develop the vaccine by autumn.





Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

IHC Market Data

Currency UK Pounds
Share Price 17.25p
Change Today 0.000p
% Change 0.00 %
52 Week High 53.50p
52 Week Low 15.85p
Volume 6,500
Shares Issued 89.66m
Market Cap £15.47m
RiskGrade 227

IHC Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
65.22% above the market average65.22% above the market average65.22% above the market average65.22% above the market average65.22% above the market average
20% below the sector average20% below the sector average20% below the sector average20% below the sector average20% below the sector average
Price Trend
88.26% below the market average88.26% below the market average88.26% below the market average88.26% below the market average88.26% below the market average
46.67% below the sector average46.67% below the sector average46.67% below the sector average46.67% below the sector average46.67% below the sector average
Income
89.56% below the market average89.56% below the market average89.56% below the market average89.56% below the market average89.56% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Growth
94.25% below the market average94.25% below the market average94.25% below the market average94.25% below the market average94.25% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

IHC Dividends

  Latest Previous
  Interim Final
Ex-Div 23-Nov-23 29-Jun-23
Paid 22-Dec-23 28-Jul-23
Amount 0.20p 0.41p

Trades for 31-Oct-2024

Time Volume / Share Price
12:02 6,500 @ 17.20p

IHC Key Personnel

COO Brook Nolson
CFO Alan Olby

Top of Page